17 studies found for:    "Noonan syndrome 5"
Show Display Options
RSS Create an RSS feed from your search for:
"Noonan syndrome 5"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects
Condition: Hepatitis C, Chronic
Intervention: Drug: IDX719 or matching placebo (oral suspension)
2 Completed Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325;   Drug: Placebo;   Drug: Peg-interferon alfa-2a;   Drug: Ribavirin
3 Completed TD-6450 SAD and MAD in Healthy Subjects
Condition: Hepatitis C
Interventions: Drug: TD-6450;   Drug: Placebo
4 Recruiting TD-6450 MAD Study in HCV Infected Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: TD-6450;   Drug: Placebo
5 Active, not recruiting Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668;   Drug: BI 207127 Dose 1;   Drug: BI 207127 Dose 2;   Drug: Faldaprevir;   Drug: Ribavirin;   Drug: BI 207127 Placebo
6 Active, not recruiting Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
7 Completed A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: HCV Infection
Interventions: Drug: GS-5885;   Drug: Placebo
8 Completed A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
9 Completed A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: PPI-461;   Drug: Placebo
10 Completed A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668;   Drug: Placebo
11 Completed Dose Ranging of GSK2336805 in Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805 40 mg;   Drug: GSK2336805 60 mg;   Drug: Pegylated interferon alpha-2a;   Drug: Ribavirin;   Drug: Telaprevir
12 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
13 Completed Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: Sovaprevir;   Drug: ACH-3102;   Drug: Ribavirin;   Drug: Placebo
14 Recruiting A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-383;   Drug: Placebo
15 Terminated GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: RBV;   Drug: PEG
16 Recruiting A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg;   Drug: JNJ-47910382 90 mg;   Drug: JNJ-47910382 200 mg;   Drug: Placebo
17 Terminated Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo;   Drug: JNJ-47910382

Indicates status has not been verified in more than two years